Ambica: One in Health

19/12/2024

https://www.facebook.com/share/v/G1XRzBUWF2868ugU/?mibextid=w8EBqM

CTTO:
5:33

03/07/2023

Congratulations!!!! Lian D Destryer Well done on winning this prestigious award. You are an inspiration to us all. 💙

12/05/2023

https://youtu.be/RjFvBcsuiEM

Aired (May 7, 2023): Doc Nielsen Donato and his team went to Cagayan de Oro to examine how a king cobra's venom affects a mammal's blood. Watch this video. ...

25/12/2022

30/11/2022

Finally Published:

Preclinical assessment of VPEAV, a new trivalent antivenom for elapid snakebite envenoming in the Philippines: Proteomics, immunoreactivity land toxicity neutralization.

29/10/2022

https://www.sciencedirect.com/science/article/abs/pii/S0041010122002938?via%3Dihub

Snakebite envenoming is an important neglected tropical disease. Antivenom supply, however, remains limited in many parts of the world. This study aim…

24/02/2022

Snakebite incidents are prevalent in our country, with an estimated number of deaths at an average of 250 deaths in a year. Despite the dreading number, the availability of antivenom remains scarce.

Currently, the only known antivenom for snakebites in the Philippines is the Philippine Cobra Antivenom that is in a monovalent form and is specifically targeted to the venom of the Philippine Cobra.

It is therefore important to develop a 𝐏𝐎𝐋𝐘𝐕𝐀𝐋𝐄𝐍𝐓 𝐀𝐍𝐓𝐈𝐕𝐄𝐍𝐎𝐌 that can treat snakebites from different species with the same toxicity level.

Ambica, through Ambitech its biopharmaceutical arm, successfully developed the anti-venom* against the following snake species:
• 𝐍𝐨𝐫𝐭𝐡𝐞𝐫𝐧 𝐏𝐡𝐢𝐥𝐢𝐩𝐩𝐢𝐧𝐞 𝐂𝐨𝐛𝐫𝐚 (𝐍𝐚𝐣𝐚 𝐍𝐚𝐣𝐚 𝐏𝐡𝐢𝐥𝐢𝐩𝐩𝐢𝐧𝐞𝐧𝐬𝐢𝐬)
• 𝐒𝐨𝐮𝐭𝐡𝐞𝐫𝐧 𝐏𝐡𝐢𝐥𝐢𝐩𝐩𝐢𝐧𝐞 𝐂𝐨𝐛𝐫𝐚 (𝐍𝐚𝐣𝐚 𝐒𝐚𝐦𝐚𝐫𝐞𝐧𝐬𝐢𝐬)
• 𝐏𝐡𝐢𝐥𝐢𝐩𝐩𝐢𝐧𝐞 𝐊𝐢𝐧𝐠 𝐂𝐨𝐛𝐫𝐚 (𝐎𝐩𝐡𝐢𝐨𝐩𝐡𝐚𝐠𝐮𝐬 𝐇𝐚𝐧𝐧𝐚𝐡)

*𝑻𝒉𝒊𝒔 𝒑𝒓𝒐𝒅𝒖𝒄𝒕 𝒊𝒔 𝑵𝑶𝑻 𝑭𝑶𝑹 𝑺𝑨𝑳𝑬 𝒂𝒏𝒅 𝒊𝒔 𝒓𝒆𝒔𝒕𝒓𝒊𝒄𝒕𝒆𝒅 𝒇𝒐𝒓 𝒖𝒔𝒆 𝒐𝒏𝒍𝒚 𝒕𝒉𝒓𝒐𝒖𝒈𝒉 𝑪𝒐𝒎𝒑𝒂𝒔𝒔𝒊𝒐𝒏𝒂𝒕𝒆 𝑺𝒑𝒆𝒄𝒊𝒂𝒍 𝑷𝒆𝒓𝒎𝒊𝒕 𝒊𝒔𝒔𝒖𝒆𝒅 𝒃𝒚 𝒕𝒉𝒆 𝑭𝑫𝑨.

15/02/2019

Mirel Activity